PM&R
Volume 2, Issue 1 , Pages 76-80 , January 2010

Low-Energy Femoral Fractures Associated With Long-Term Bisphosphonate Use in a Rehabilitation Setting: A Case Series

  • Robert D. Bunning, MD

      Affiliations

    • Division of Rehabilitation Medicine and Division of Medicine, National Rehabilitation Hospital, 102 Irving St NW, Room 2135, Washington DC, 20010†
    • Corresponding Author InformationAddress correspondence to: R.D.B.
    • ,
  • Robert J. Rentfro, MD

      Affiliations

    • Division of Rehabilitation Medicine and Division of Medicine, National Rehabilitation Hospital, Washington, DC‡
    • ,
  • James S. Jelinek, MD

      Affiliations

    • Division of Rehabilitation Medicine and Division of Medicine, National Rehabilitation Hospital, Washington, DC§

Received 18 August 2009 ,Accepted 19 November 2009.

References 

  1. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment, (Flex): A randomized trial. JAMA. 2006;296:2927–2938
  2. Bone HG, Hosking D, Devogelaer JP, et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–1199
  3. Ovinda CV, Zerwekh JE, Rao S, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301
  4. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304–1306
  5. Goh SK, Yang KY, Koh JSB, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br. 2007;89:349–353
  6. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–350
  7. Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Safety. 2009;32:775–785
  8. Reina AV, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355:2048–2050
  9. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy. Injury. 2008;39:224–231
  10. Lenart BA, Lorich DG, Lane JM. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359:317–318
  11. Wernecke G, Namduri S, DiCarlo EF, et al. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSSJ. 2008;4:123–127
  12. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006;91:2631–2637

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)01586-X

doi: 10.1016/j.pmrj.2009.11.007

PM&R
Volume 2, Issue 1 , Pages 76-80 , January 2010

Article Tools

* Image Usage & Resolution